In a safety announcement, FDA notified the public that that an additional concentration of liquid acetaminophen marketed for "infants" (160 mg/5 mL) is now available at local stores.
In a safety announcement, FDA notified the public that an additional concentration of liquid acetaminophen marketed for "infants" (160 mg/5 mL) is now available at local stores. Until now, only more concentrated versions of liquid acetaminophen have been available for infants. The higher concentrations of these older versions are 80 mg/0.8 mL and 80 mg/mL and continue to be available on store shelves, and in homes.
The availability of this new concentration follows the recommendation from a 2009 joint meeting of the FDA Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee that only 1 concentration of pediatric liquid acetaminophen be made available over the counter. Products with different concentrations can cause dosing confusion among parents and caregivers that may lead to unintentional overdoses in pediatric patients.
In order to prevent possible dosing confusion between products with different concentrations of acetaminophen, many manufacturers voluntarily changed the higher concentrated liquid acetaminophen marketed for infants to make it the same lower concentration (160 mg/5 mL) as the product recently marketed for older children. The transition to the new concentration started earlier this year, however, products with varying strengths of liquid acetaminophen are still in stores and consumers' medicine cabinets.
“It will be up to manufacturers to determine whether they will stop making the 80-mg/0.8-mL and 80-mg/mL concentrations of liquid acetaminophen,” FDA noted. “Therefore, it is important for consumers to carefully read the Drug Facts label on the package to identify the strength, dosage, and directions for use for this product. Consumers should always check with a healthcare professional if they have any questions about medications they are using.”
FDA advises that healthcare professionals provide directions to patients that specify the concentration and dose of liquid acetaminophen that should be given to any child under aged 12 years. In addition, the agency says the concentration of liquid acetaminophen should be included on a prescription because of the multiple products and concentrations that are available.
“Healthcare professionals should use their clinical judgment to recommend the most appropriate liquid acetaminophen product for children under the age of 12, and they should counsel caregivers on product differences,” the agency advised.
Healthcare professionals should report adverse events or medication errors involving over-the-counter infant acetaminophen products to the FDA MedWatch program here.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.